TRAW Traws Pharma, Inc.: institutional ownership and insider trading
34 funds reported holding $5.29M of Traws Pharma, Inc. in their latest 13F filings; in Q2 2026 funds net bought $2.14M, with 12 new positions and 7 funds selling out; over the last 12 months insiders bought $998K and sold $0 on the open market.
TRAW revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$3.05M, EPS -0.16
- Quarter ended Mar 31, 2026: revenue n/a, net income −$7.11M, EPS -0.53
- Quarter ended Dec 31, 2025: revenue n/a, net income −$7.44M, EPS -0.82
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.96M, EPS -0.34
Largest institutional holders of TRAW
- ORBIMED ADVISORS LLC — $1.01M
- Ally Bridge Group (NY) LLC — $663K
- ADAGE CAPITAL PARTNERS GP, L.L.C. — $616K
- ADAR1 Capital Management, LLC — $504K
- Lynx1 Capital Management LP — $472K
- Ikarian Capital, LLC — $403K
- SPHERA FUNDS MANAGEMENT LTD. — $336K
- VANGUARD CAPITAL MANAGEMENT LLC — $278K
- JANE STREET GROUP, LLC — $182K
- Alyeska Investment Group, L.P. — $139K
Recent TRAW insider trades
- Apr 16, 2026: Orbimed Advisors Llc bought 597,729 shares ($998K)
5%+ owners
- ORBIMED ADVISORS LLC: 11.9% (Schedule 13D/A, filed May 5, 2026)
- Sirenia Capital Management LP: 9.9% (Schedule 13G, filed Aug 14, 2026)
- Ikarian Capital, LLC: 9.5% (Schedule 13G/A, filed Aug 14, 2026)
- Perceptive Advisors LLC: 6.1% (Schedule 13G/A, filed May 15, 2026)